Document 1173
 DOCN  M94A1173
 TI    Obstetrics pathology in HIV positive pregnant women.
 DT    9412
 AU    Carreras R; Torrent A; Rovira MT; Paya A; Soriano RM; Xercavins J; Dept.
       Obstetrics and Gynecology, Autonomus University of; Barcelona, Spain.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):192 (abstract no. PB0783). Unique
       Identifier : AIDSLINE ICA10/94371402
 AB    GOALS: Analisys of obstetric pathology prevalence in HIV positive
       pregnant women, compared to a control group. PATIENTS AND METHODS: We
       studied 172 HIV positive pregnant women and a control group of 172 HIV
       women negative pregnant women that delivered at our hospital facilities
       from 1985 to 1993. Together with a careful clinical history, whit
       special concern in obstetric pathology, we performed cardiotocographic
       monitoring in all of them, as well as evaluated the newborn state by
       measurements of umbilical blood pH. RESULTS: we found an 18.6% of
       prematurity in HIV positive women, versus a 7.5% in the control group,
       which is statiscally significant, OD: 2.80 95% IC (1.35-5.87).
       Prevalence of prematurity considerina drug addiction in the HIV positive
       group was studied. A 24.3% of prematurity was found in the active drug
       addict group versus a 8.5% in the former drug addicts, which is also
       statistically significant. OD: 3.47 95% IC = (1.17-10.99). We found a
       20% prevalence of intrauterine growth retardation in the HIV positive
       group, versus a 3% in the control group, which is statistically
       significant, OD = 8.53 95% IC (3.08-25.52). We have not found
       significant differences between prevalence in both groups when studying
       premature membrane rupture, placenta previa or premature normally
       inserted placenta separation. It is remarkable the lower incidence of
       gestational hypertension in the HIV positive group, which is
       statistically significant. Comparison of fetal monitoring in both groups
       does not show significant differences. CONCLUSION: There is a higher
       rate of prematurity in HIV positive intravenous drugs ussers, while
       former drug users do not show statistical diference with the control
       group. Incidence of intrauterine growth retardation is higher in the HIV
       positive group, while there are not significant differences in premature
       rupture of membranes, placenta previa or premature normally inserted
       placenta separation. There is higher incidence of fetal distress HIV
       positive pregnant women.
 DE    Comparative Study  Female  Fetal Growth Retardation/*EPIDEMIOLOGY  Fetal
       Membranes, Premature Rupture/EPIDEMIOLOGY  Human
       Hypertension/EPIDEMIOLOGY  *HIV Seropositivity  Incidence  Infant,
       Newborn  *Infant, Premature  Placenta Praevia/EPIDEMIOLOGY  Pregnancy
       Pregnancy Complications/*EPIDEMIOLOGY/PHYSIOPATHOLOGY  Pregnancy
       Complications, Cardiovascular/EPIDEMIOLOGY  Pregnancy Complications,
       Infectious/*EPIDEMIOLOGY/PHYSIOPATHOLOGY  Prevalence  Spain/EPIDEMIOLOGY
       Substance Abuse, Intravenous  *Substance Dependence  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).